Avas Special Precautions

Rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class. Avas may cause an elevation in serum CPK levels. This should be considered in the differential diagnosis of chest pain in patients on therapy with Avas. Uncomplicated myalgia has been reported in Avas-treated patients. Avas therapy should be discontinued if markedly elevated CPK levels occurred or myopathy is diagnosed or suspected.
The risk of myopathy during treatment with other drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, niacin or azole antifungals. Patients should be advised to report promptly any unexplained muscle pain, tenderness or weakness, particularly, if accompanied by malaise or fever.
Use in children: Safety and efficacy of Avas have not been established.
Use in the elderly: Efficacy and safety in older patients using recommended dose is similar to that seen in general population.